Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes.

Kaku K, Rasmussen MF, Clauson P, Seino Y

Diabetes, obesity & metabolism1 Apr 2010Cited by 73 (Europe PMC)

PMID20380655DOI10.1111/j.1463-1326.2009.01194.xPepBankPUB-20380655

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes on a sulphonylurea, liraglutide 0.9 mg lowered HbA1c more than placebo at week 24.
In plain wordsIn Japanese adults with type 2 diabetes on a sulphonylurea, liraglutide 0.9 mg lowered HbA1c more than placebo.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change at week 24, 0.9 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.9 mg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
HbA1c change
−1.56%
liraglutide 0.9 mg
HbA1c change
−0.4%
placebo
Source sentences
Summary
The mean change in HBA1c from baseline to week 24 (LOCF) was -1.56 (s.d. 0.84) and -1.46 (s.d. 0.95) with liraglutide 0.9 and 0.6 mg respectively, and -0.40 (s.d. 0.93) with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Mean HBA1c at week 24 of the two liraglutide groups were significantly lower than the placebo group (p < 0.0001 for both).
Summary · context
liraglutide were compared in 264 Japanese subjects [mean body mass index (BMI) 24.9 kg/m(2); mean glycated haemoglobin (HBA1c) 8.4%] randomized and exposed to receive liraglutide 0.6 mg/day (n = 88), 0.9 mg/day (n = 88) or placebo (n = 88) each added to SU monotherapy (glibenclamide, glicazide or gl…
Report a problemFND-2038065501
02HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes on a sulphonylurea, liraglutide 0.6 mg lowered HbA1c more than placebo at week 24.
In plain wordsIn Japanese adults with type 2 diabetes on a sulphonylurea, liraglutide 0.6 mg lowered HbA1c more than placebo.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change at week 24, 0.6 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 mg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
HbA1c change
−1.46%
liraglutide 0.6 mg
HbA1c change
−0.4%
placebo
Source sentences
Summary
The mean change in HBA1c from baseline to week 24 (LOCF) was -1.56 (s.d. 0.84) and -1.46 (s.d. 0.95) with liraglutide 0.9 and 0.6 mg respectively, and -0.40 (s.d. 0.93) with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Mean HBA1c at week 24 of the two liraglutide groups were significantly lower than the placebo group (p < 0.0001 for both).
Summary · context
liraglutide were compared in 264 Japanese subjects [mean body mass index (BMI) 24.9 kg/m(2); mean glycated haemoglobin (HBA1c) 8.4%] randomized and exposed to receive liraglutide 0.6 mg/day (n = 88), 0.9 mg/day (n = 88) or placebo (n = 88) each added to SU monotherapy (glibenclamide, glicazide or gl…
Report a problemFND-2038065502
03HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes on a sulphonylurea, more subjects reached HbA1c below 7.0% with liraglutide 0.9 mg than with placebo.
In plain wordsMore people reached HbA1c below 7.0% with liraglutide 0.9 mg than with placebo.
Peptide
Liraglutide
Outcome
IncreaseProportion with HbA1c below 7.0%, 0.9 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.9 mg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Proportion HbA1c <7.0%
71.3%
liraglutide 0.9 mg
Proportion HbA1c <7.0%
14.8%
placebo
Source sentences
Summary
More subjects reached HBA1c < 7.0% with liraglutide (0.6 mg: 46.5%; 0.9 mg: 71.3%) vs. placebo (14.8%).
1 context sentence(design, population, supporting numbers)
Summary · context
liraglutide were compared in 264 Japanese subjects [mean body mass index (BMI) 24.9 kg/m(2); mean glycated haemoglobin (HBA1c) 8.4%] randomized and exposed to receive liraglutide 0.6 mg/day (n = 88), 0.9 mg/day (n = 88) or placebo (n = 88) each added to SU monotherapy (glibenclamide, glicazide or gl…
Report a problemFND-2038065503
04HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes on a sulphonylurea, more subjects reached HbA1c below 7.0% with liraglutide 0.6 mg than with placebo.
In plain wordsMore people reached HbA1c below 7.0% with liraglutide 0.6 mg than with placebo.
Peptide
Liraglutide
Outcome
IncreaseProportion with HbA1c below 7.0%, 0.6 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 mg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Proportion HbA1c <7.0%
46.5%
liraglutide 0.6 mg
Proportion HbA1c <7.0%
14.8%
placebo
Source sentences
Summary
More subjects reached HBA1c < 7.0% with liraglutide (0.6 mg: 46.5%; 0.9 mg: 71.3%) vs. placebo (14.8%).
1 context sentence(design, population, supporting numbers)
Summary · context
liraglutide were compared in 264 Japanese subjects [mean body mass index (BMI) 24.9 kg/m(2); mean glycated haemoglobin (HBA1c) 8.4%] randomized and exposed to receive liraglutide 0.6 mg/day (n = 88), 0.9 mg/day (n = 88) or placebo (n = 88) each added to SU monotherapy (glibenclamide, glicazide or gl…
Report a problemFND-2038065504
05HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes on a sulphonylurea, fasting plasma glucose was significantly lower with liraglutide 0.9 mg than with placebo.
In plain wordsLiraglutide 0.9 mg lowered fasting blood glucose more than placebo in Japanese adults with type 2 diabetes on a sulphonylurea.
Peptide
Liraglutide
Outcome
DecreaseFasting plasma glucose, 0.9 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.9 mg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
FPG difference vs placebo
−1.8 mmol/l
liraglutide 0.9 mg
Source sentences
Summary
Fasting plasma glucose (FPG) levels were significantly improved with liraglutide (difference -1.47 mmol/l and -1.80 mmol/l with 0.6 and 0.9 mg vs. placebo; p < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
liraglutide were compared in 264 Japanese subjects [mean body mass index (BMI) 24.9 kg/m(2); mean glycated haemoglobin (HBA1c) 8.4%] randomized and exposed to receive liraglutide 0.6 mg/day (n = 88), 0.9 mg/day (n = 88) or placebo (n = 88) each added to SU monotherapy (glibenclamide, glicazide or gl…
Report a problemFND-2038065505
06HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes on a sulphonylurea, fasting plasma glucose was significantly lower with liraglutide 0.6 mg than with placebo.
In plain wordsLiraglutide 0.6 mg lowered fasting blood glucose more than placebo in Japanese adults with type 2 diabetes on a sulphonylurea.
Peptide
Liraglutide
Outcome
DecreaseFasting plasma glucose, 0.6 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 mg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
FPG difference vs placebo
−1.47 mmol/l
liraglutide 0.6 mg
Source sentences
Summary
Fasting plasma glucose (FPG) levels were significantly improved with liraglutide (difference -1.47 mmol/l and -1.80 mmol/l with 0.6 and 0.9 mg vs. placebo; p < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
liraglutide were compared in 264 Japanese subjects [mean body mass index (BMI) 24.9 kg/m(2); mean glycated haemoglobin (HBA1c) 8.4%] randomized and exposed to receive liraglutide 0.6 mg/day (n = 88), 0.9 mg/day (n = 88) or placebo (n = 88) each added to SU monotherapy (glibenclamide, glicazide or gl…
Report a problemFND-2038065506
07HumanRandomized controlled trialSafety outcome
In Japanese adults on a sulphonylurea, 77 minor hypoglycaemic episodes occurred with liraglutide 0.9 mg and 38 with placebo, all with sulphonylurea.
In plain wordsThere were 77 minor low blood sugar episodes with liraglutide 0.9 mg and 38 with placebo, all alongside a sulphonylurea.
Peptide
Liraglutide
Outcome
Direction not reportedMinor hypoglycaemic episodes, 0.9 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.9 mg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Minor hypoglycaemic episodes
77 episodes
liraglutide 0.9 mg
Minor hypoglycaemic episodes
38 episodes
placebo
Source sentences
Summary
Overall safety was similar between treatments: no major hypoglycaemic episodes were reported, while 84/77/38 minor hypoglycaemic episodes occurred in the 0.6 mg/0.9 mg and placebo treatment groups (all in combination with SU), reflecting lower ambient glucose levels.
1 context sentence(design, population, supporting numbers)
Summary · context
liraglutide were compared in 264 Japanese subjects [mean body mass index (BMI) 24.9 kg/m(2); mean glycated haemoglobin (HBA1c) 8.4%] randomized and exposed to receive liraglutide 0.6 mg/day (n = 88), 0.9 mg/day (n = 88) or placebo (n = 88) each added to SU monotherapy (glibenclamide, glicazide or gl…
Report a problemFND-2038065507
08HumanRandomized controlled trialSafety outcome
In Japanese adults on a sulphonylurea, 84 minor hypoglycaemic episodes occurred with liraglutide 0.6 mg and 38 with placebo, all with sulphonylurea.
In plain wordsThere were 84 minor low blood sugar episodes with liraglutide 0.6 mg and 38 with placebo, all alongside a sulphonylurea.
Peptide
Liraglutide
Outcome
Direction not reportedMinor hypoglycaemic episodes, 0.6 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.6 mg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Minor hypoglycaemic episodes
84 episodes
liraglutide 0.6 mg
Minor hypoglycaemic episodes
38 episodes
placebo
Source sentences
Summary
Overall safety was similar between treatments: no major hypoglycaemic episodes were reported, while 84/77/38 minor hypoglycaemic episodes occurred in the 0.6 mg/0.9 mg and placebo treatment groups (all in combination with SU), reflecting lower ambient glucose levels.
1 context sentence(design, population, supporting numbers)
Summary · context
liraglutide were compared in 264 Japanese subjects [mean body mass index (BMI) 24.9 kg/m(2); mean glycated haemoglobin (HBA1c) 8.4%] randomized and exposed to receive liraglutide 0.6 mg/day (n = 88), 0.9 mg/day (n = 88) or placebo (n = 88) each added to SU monotherapy (glibenclamide, glicazide or gl…
Report a problemFND-2038065508
09HumanRandomized controlled trialSafety outcome
In Japanese adults on a sulphonylurea, no major hypoglycaemic episodes were reported with liraglutide or placebo.
In plain wordsNo major low blood sugar episodes were reported with liraglutide or placebo in Japanese adults on a sulphonylurea.
Peptide
Liraglutide
Outcome
No significant changeMajor hypoglycaemic episodes
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.6 and 0.9 mg/day · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
no major hypoglycaemic episodes were reported
1 context sentence(design, population, supporting numbers)
Summary · context
liraglutide were compared in 264 Japanese subjects [mean body mass index (BMI) 24.9 kg/m(2); mean glycated haemoglobin (HBA1c) 8.4%] randomized and exposed to receive liraglutide 0.6 mg/day (n = 88), 0.9 mg/day (n = 88) or placebo (n = 88) each added to SU monotherapy (glibenclamide, glicazide or gl…
Report a problemFND-2038065509
10HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes on a sulphonylurea, liraglutide 0.9 mg caused no relevant change in mean body weight, while weight fell with placebo.
In plain wordsLiraglutide 0.9 mg did not change body weight in a relevant way, while weight fell on placebo.
Peptide
Liraglutide
Outcome
No significant changeBody weight change, 0.9 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
0.9 mg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Weight change
−0.37 kg
liraglutide 0.9 mg
Weight change
−1.12 kg
placebo
Source sentences
Summary
No relevant change in mean body weight occurred in subjects receiving liraglutide (0.6 mg: 0.06 kg; 0.9 mg: -0.37 kg), while mean body weight decreased in subjects receiving placebo (-1.12 kg).
1 context sentence(design, population, supporting numbers)
Summary · context
liraglutide were compared in 264 Japanese subjects [mean body mass index (BMI) 24.9 kg/m(2); mean glycated haemoglobin (HBA1c) 8.4%] randomized and exposed to receive liraglutide 0.6 mg/day (n = 88), 0.9 mg/day (n = 88) or placebo (n = 88) each added to SU monotherapy (glibenclamide, glicazide or gl…
Report a problemFND-2038065510
11HumanRandomized controlled trialEfficacy outcome
In Japanese adults with type 2 diabetes on a sulphonylurea, liraglutide 0.6 mg caused no relevant change in mean body weight, while weight fell with placebo.
In plain wordsLiraglutide 0.6 mg did not change body weight in a relevant way, while weight fell on placebo.
Peptide
Liraglutide
Outcome
No significant changeBody weight change, 0.6 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
0.6 mg/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Weight change
0.06 kg
liraglutide 0.6 mg
Weight change
−1.12 kg
placebo
Source sentences
Summary
No relevant change in mean body weight occurred in subjects receiving liraglutide (0.6 mg: 0.06 kg; 0.9 mg: -0.37 kg), while mean body weight decreased in subjects receiving placebo (-1.12 kg).
1 context sentence(design, population, supporting numbers)
Summary · context
liraglutide were compared in 264 Japanese subjects [mean body mass index (BMI) 24.9 kg/m(2); mean glycated haemoglobin (HBA1c) 8.4%] randomized and exposed to receive liraglutide 0.6 mg/day (n = 88), 0.9 mg/day (n = 88) or placebo (n = 88) each added to SU monotherapy (glibenclamide, glicazide or gl…
Report a problemFND-2038065511

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00395746

Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 264Oct 2006 to May 2008

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 8 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.